Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck’s comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 in Vienna, Austria.1 “In the BIRCH trial the PD-L1 antibody atezolizumab showed a remarkable activity in a large number of patients regardless of the line of treatment ,” said Reck.
